Join to access to all OVN content. Join for Free

Results for 'oncologic biosimilars'

Biosimilars: what the oncologist should know
OVN Avatar Marc Thill, Nicholas Thatcher, Vladimir Hanes & Gary H. Lyman
Biosimilars: what the oncologist should know

biosimilars, extrapolation, monoclonal antibodies, oncologic biosimilars

As originator biologic medicines lose patent protection, biopharmaceutical companies are developing biosimilars. Biosimilars are similar versions of costly and complex therapies aimed at providing more affordable treatment options. Many biosimilars are now approved worldwide, with several m…

Dec 18th • 25 mins read

Related Topics

Loading...